Citations

Clear

2429 citation(s) found for "Shah, SS".

Defining Rates and Risk Factors for Readmissions Following Emergency General Surgery
Havens, Joaquim M. , Olufajo, Olubode A. , Cooper, Zara , Haider, Adil H. , Shah, Adil A. , Salim, Alí , Cooper, Zara

Mayo Clinic

JAMA Surgery | November 11, 2015 | Volume: 151 | Issue: 4 | Pages: 330

10.1001/jamasurg.2015.4056 | PMID 26559368 Get It

Predicting the Overuse of PCSK-9 Inhibitors
Rodríguez‐Gutiérrez, René , Shah, Nilay D. , Montori, Víctor M. , Montori, Victor M

Mayo Clinic

JAMA | November 8, 2015 | Volume: 314 | Issue: 18 | Pages: 1909

10.1001/jama.2015.13414 | PMID 26547456 Get It

Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation
Yao, Xiaoxi , Deshmukh, Abhishek , Houten, Holly Van, Sangaralingham, Lindsey R. , Siontis, Konstantinos C. , Piccini, Jonathan P. , Asirvatham, Samuel J. , Friedman, Paul A. , Packer, Douglas L. , Shah, Nilay D. , Van Houten, Holly, Noseworthy, Peter A. , Gersh, Bernard J. , Asirvatham, Samuel J , Yao, Xiaoxi

Mayo Clinic

Journal of the American Heart Association | November 6, 2015 | Volume: 4 | Issue: 11 | Pages: No page available

10.1161/jaha.115.002597 | PMID 26541393 Get It

Background There is significant practice variation in oral anticoagulation ( OAC ) use following catheter ablation for atrial fibrillation. It is not clear whether the risk of cardioembolism increases after discontinuation of OAC following catheter ablation. Methods and Results We identified 6886 patients within a large national administrative claims database who underwent catheter ablation for atrial fibrillation between January 1, 2005, and September 30, 2014. We assessed the effect of time off of OAC by CHA 2 DS 2 ‐ VAS c score (after adjusting for other comorbidities) on risk of cardioembolism, using Cox proportional hazards models. There was an increase in the use of non–vitamin K OAC after ablation from 0% in 2005 to 69.8% in 2014. OAC discontinuation was high, with only 60.5% and 31.3% of patients remaining on OAC at 3 and 12 months, respectively. The rate of discontinuation was higher in low‐risk patients (82% versus 62.5% at 12 months for CHA 2 DS 2 ‐ VAS c 0–1 versus ≥2, respectively; P <0.001). Stroke occurred in 1.4% of patients with CHA 2 DS 2 ‐ VAS c ≥2 and 0.3% of those with CHA 2 DS 2 ‐ VAS c 0 or 1 over the study follow‐up. The risk of cardioembolism in the first 3 months after ablation was increased among those with any time off OAC (hazard ratio 8.06 [95% CI 1.53–42.3], P <0.05). The risk of cardioembolism beyond 3 months was increased with OAC discontinuation among high‐risk patients (hazard ratio 2.48 [95% CI 1.11–5.52], P <0.05) but not low‐risk patients. Conclusion The overall risk of stroke in postablation patients is low; however, OAC discontinuation after ablation is common and is associated with increased risk of cardioembolism for all patients within the first 3 months and for high‐risk patients in the long term. Continuing OAC for at least 3 months in all patients and indefinitely in high‐risk patients appears to be the safest strategy.
Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance)
Brown, Paul D. , Anderson, S. Keith , Carrero, Xiomara W., Galanis, E., Shah, Sunjay, Abrams, Ross A. , Curran, Walter J. , Buckner, Jan C. , Shaw, Edward G. , O'Neill, Brian P, Galanis, Eva, Shah, Sunjay A, O’Neill, Brian Patrick , Giannini, Caterina

Mayo Clinic

Neuro-Oncology Practice | November 5, 2015 | Volume: 2 | Issue: 4 | Pages: 199-204

10.1093/nop/npv031 | PMID 26640699 Get It

Abstract Background Pilocytic astrocytoma is a rare tumor in adults. This report is of a prospective clinical trial with long-term follow-up. Methods Between 1986 and 1994, 20 eligible adults with supratentorial pilocytic astrocytomas were enrolled in a prospective intergroup trial of radiotherapy (RT) after biopsy (3 patients) or observation after gross (11 patients) or subtotal (6 patients) resection. Results At the time of analysis (median follow-up, 20.8 years), 2 patients (10%) have died and 18 patients (90%) are alive. Neurologic and cognitive function were stable or improved over time for the majority of patients. No toxic effects of treatment or malignant transformations have been recorded at last follow-up. For the entire cohort the 20-year time to progression and overall survival rates are 95% and 90% respectively. The cause of death (2.2 and 16.1 years after enrollment) in both patients was unrelated to tumor although both were biopsy-only patients. One subtotally resected tumor progressed 1 month after enrollment requiring P32 injection into an enlarging cyst. Because of further progression this patient required RT 18 months later. This patient is alive without evidence of progression 18 years after RT. Conclusion The long-term follow-up results of this prospective trial confirm that adults with pilocytic astrocytomas have a favorable prognosis with regard to survival and neurologic function. Close observation is recommended for adults with pilocytic astrocytomas, reserving RT for salvage, as the majority remain stable after gross or subtotal resection and no adjuvant therapy.
Evaluation of the Perceived Association Between Resident Turnover and the Outcomes of Patients Who Undergo Emergency General Surgery
Shah, Adil A. , Zogg, Cheryl K. , Nitzschke, Stephanie , Changoor, Navin R. , Havens, Joaquim M. , Salim, Alí , Cooper, Zara , Haider, Adil H.

Mayo Clinic

JAMA Surgery | November 4, 2015 | Volume: 151 | Issue: 3 | Pages: 217

10.1001/jamasurg.2015.3940 | PMID 26536282 Get It

TCF7L2 Genotype and α-Cell Function in Humans Without Diabetes
Varghese, Ron T. , Miles, John M., Piccinini, Francesca, Man, Chiara Dalla , Bailey, Kent R. , Rizza, Robert A., Shah, Mithun V , Miles, John M., Cobelli, Claudio , Vella, Adrian , Dalla Man, Chiara

Mayo Clinic

Diabetes | November 3, 2015 | Volume: 65 | Issue: 2 | Pages: 371-380

10.2337/db15-1233 | PMID 26525881 Get It

The diabetes-associated allele in TCF7L2 increases the rate of conversion to diabetes; however, the mechanism by which this occurs remains elusive. We hypothesized that the diabetes-associated allele in this locus (rs7903146) impairs insulin secretion and that this defect would be exacerbated by acute free fatty acid (FFA)–induced insulin resistance. We studied 120 individuals of whom one-half were homozygous for the diabetes-associated allele TT at rs7903146 and one-half were homozygous for the protective allele CC. After a screening examination during which glucose tolerance status was determined, subjects were studied on two occasions in random order while undergoing an oral challenge. During one study day, FFA was elevated by infusion of Intralipid plus heparin. On the other study day, subjects received the same amount of glycerol as present in the Intralipid infusion. β-Cell responsivity indices were estimated with the oral C-peptide minimal model. We report that β-cell responsivity was slightly impaired in the TT genotype group. Moreover, the hyperbolic relationship between insulin secretion and β-cell responsivity differed significantly between genotypes. Subjects also exhibited impaired suppression of glucagon after an oral challenge. These data imply that a genetic variant harbored within the TCF7L2 locus impairs glucose tolerance through effects on glucagon as well as on insulin secretion.
Temporal Trends of Cardiac Chambers Function with Trastuzumab in Human Epidermal Growth Factor Receptor II–Positive Breast Cancer Patients
Moustafa, Sherif, Murphy, Katie , Nelluri, B.K., Northfelt, Donald W. , Shah, Parth , Lee, Howard , Wilansky, Susan , Naqvi, Tasneem Z. , Meyer, Susan M. , Mookadam, Farouk , Nelluri, Bhargava K, Northfelt, Donald, Meyer, Susan, Mookadam, Farouk

Mayo Clinic

Echocardiography | October 24, 2015 | Volume: 33 | Issue: 3 | Pages: 406-415

10.1111/echo.13087 | PMID 26498324 Get It

BackgroundTrastuzumab has substantially improved overall survival and reduced the risk of disease recurrence in patients with human epidermal growth factor receptor type II (HER‐II)–positive breast cancer. However, this benefit may be at the increased risk of cardiotoxicity. We aimed to explore the early subclinical left and right ventricular as well as atrial dysfunction, in trastuzumab‐treated patients with HER‐II–positive breast cancer, using velocity vector imaging.MethodsEchocardiography images were acquired in 50 patients with HER‐II–positive breast cancer undergoing trastuzumab therapy. All patients had baseline and 3–6 months and 12–15 months of follow‐up echocardiograms after initiation of trastuzumab therapy. Subendocardial borders of all the cardiac chambers were traced from the apical views to obtain volumetric and deformation indices.ResultsMean age was 60 ± 13 years. Left ventricular (LV) ejection fraction as well as conventional indices of right ventricular (RV) function did not change with trastuzumab. The RV peak systolic global longitudinal strain (GLε) significantly decreased (−24.53 ± 6.03 vs. −21.28 ± 5.11 vs. −21.84 ± 5.15, baseline vs. first and second follow‐ups, P = 0.01). LV peak systolic GLε was reduced by 1.19 at early follow‐up (P < 0.05). Left atrial reservoir and booster pump functions as well as right atrial reservoir function were reduced through follow‐up as well.ConclusionsThe RV exhibited greater change in strain after trastuzumab treatment when compared to the LV. Atria function was reduced by trastuzumab as well. The repercussion of these findings and their potential implication will warrant further study.
Managing alcoholic liver disease
Shah, Vijay H.

Mayo Clinic

Clinical and Molecular Hepatology | October 19, 2015 | Volume: 21 | Issue: 3 | Pages: 212

10.3350/cmh.2015.21.3.212 | PMID 26523266 Get It

Can statistical linkage of missing variables reduce bias in treatment effect estimates in comparative effectiveness research studies?
Chang, Jessica , Olson, Melvin , Kahler, Kristijan H. , Swindle, Jason , Buzinec, Paul, Shah, N. C., Shah, Nilay , Crown, William H. , Shah, Nilay, Borah, Bijan J.

Mayo Clinic

Journal of Comparative Effectiveness Research | October 5, 2015 | Volume: 4 | Issue: 5 | Pages: 455-463

10.2217/cer.15.23 | PMID 26436848 Get It

Aim: Missing data, particularly missing variables, can create serious analytic challenges in observational comparative effectiveness research studies. Statistical linkage of datasets is a potential method for incorporating missing variables. Prior studies have focused upon the bias introduced by imperfect linkage. Methods: This analysis uses a case study of hepatitis C patients to estimate the net effect of statistical linkage on bias, also accounting for the potential reduction in missing variable bias. Results: The results show that statistical linkage can reduce bias while also enabling parameter estimates to be obtained for the formerly missing variables. Conclusion: The usefulness of statistical linkage will vary depending upon the strength of the correlations of the missing variables with the treatment variable, as well as the outcome variable of interest.
Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation
Spratt, Daniel E. , Doran, Michael G. , Lee, Man Xia, Shah, Neel , Wongvipat, John, Carnazza, Kathryn E., Klee, George G., Polkinghorn, William R., Tindall, Donald J., Lewis, Jason S. , Davis, Brian J. , Evans, Michael J. , Lee, Man Xia, Sawyers, Charles L. , Spratt, Daniel E

Mayo Clinic

Cancer Research | October 2, 2015 | Volume: 75 | Issue: 22 | Pages: 4688-4696

10.1158/0008-5472.can-15-0892 | PMID 26432404 Get It

Abstract Clinical trials have established the benefit of androgen deprivation therapy (ADT) combined with radiotherapy in prostate cancer. ADT sensitizes prostate cancer to radiotherapy-induced death at least in part through inhibition of DNA repair machinery, but for unknown reasons, adjuvant ADT provides further survival benefits. Here, we show that androgen receptor (AR) expression and activity are durably upregulated following radiotherapy in multiple human prostate cancer models in vitro and in vivo. Moreover, the degree of AR upregulation correlates with survival in vitro and time to tumor progression in animal models. We also provide evidence of AR pathway upregulation, measured by a rise in serum levels of AR-regulated hK2 protein, in nearly 20% of patients after radiotherapy. Furthermore, these men were three-fold more likely to experience subsequent biochemical failure. Collectively, these data demonstrate that radiotherapy can upregulate AR signaling after therapy to an extent that negatively affects disease progression and/or survival. Cancer Res; 75(22); 4688–96. ©2015 AACR.